OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
384470$3405.0057

CoreLine Soft Co Ltd

Advanced Medical Equipment & TechnologyVerified

CoreLine Soft has a market price of 3,405 KRW and a market capitalization of 62,569,006,530 KRW, with a price-to-book ratio of 3.44 and a price-to-tangible-book ratio of 3.44. The company's enterprise value to EBITDA is -5.72, and its enterprise value to revenue is 17.94, indicating a high valuation relative to its revenue but a negative EBITDA. The company's return on equity is -79.77%, and its return on assets is -35.54%, both significantly below industry norms. The company's profitability is challenged, with a net loss of 14,496,260,920 KRW and an operating loss of 13,444,847,760 KRW. Its gross profit of 3,933,580,050 KRW is modest compared to its total revenue of 4,283,668,050 KRW, indicating high cost structures or low pricing power. The company's debt-to-equity ratio is 0.79, and its current ratio is 1.45, suggesting moderate liquidity but a need for careful debt management. CoreLine Soft's revenue is concentrated in a single business segment focused on AI-based medical image analysis software, with no disclosed geographic diversification. The company's operating cash flow is negative at -11,614,606,740 KRW, and its free cash flow is -17,069,904,670 KRW, indicating a reliance on external financing. Capital expenditures of -3,395,745,750 KRW suggest ongoing investment in infrastructure or technology. The company's outlook for the current fiscal year is uncertain, with no disclosed revenue growth or decline. The company's historical revenue of 4,283,668,050 KRW is relatively flat, and there is no indication of a significant growth trajectory. The company's risk assessment indicates medium liquidity risk and low dilution risk, but key flags include negative net cash after subtracting total debt. Recent events and filings do not provide specific details on the company's strategic initiatives or financial performance. The company's financial health is constrained by its negative operating and net income, and its reliance on external financing to sustain operations. The company's capital structure and liquidity position require close monitoring to assess its ability to meet short-term obligations. The company's risk profile is influenced by its high debt levels and negative cash flows, which could impact its ability to invest in growth opportunities. The company's dilution risk is low, but its liquidity risk remains a concern due to its negative net cash position. The company's financial performance and strategic direction will be critical in determining its long-term viability.

30-day price · 384470+315.00 (+10.2%)
Low$2975.00High$4050.00Close$3395.00As of21 May, 00:00 UTC
Profile
CompanyCoreLine Soft Co Ltd
Ticker384470.KQ
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. CoreLine Soft Co Ltd develops and supplies artificial intelligence (AI) based medical image analysis software for computed tomography (CT) images of the chest, head, and neck, primarily assisting medical staff in diagnosis and treatment support.

Classification. CoreLine Soft is classified in the Healthcare sector under the Advanced Medical Equipment & Technology industry with a confidence level of 0.92.

CoreLine Soft has a market price of 3,405 KRW and a market capitalization of 62,569,006,530 KRW, with a price-to-book ratio of 3.44 and a price-to-tangible-book ratio of 3.44. The company's enterprise value to EBITDA is -5.72, and its enterprise value to revenue is 17.94, indicating a high valuation relative to its revenue but a negative EBITDA. The company's return on equity is -79.77%, and its return on assets is -35.54%, both significantly below industry norms. The company's profitability is challenged, with a net loss of 14,496,260,920 KRW and an operating loss of 13,444,847,760 KRW. Its gross profit of 3,933,580,050 KRW is modest compared to its total revenue of 4,283,668,050 KRW, indicating high cost structures or low pricing power. The company's debt-to-equity ratio is 0.79, and its current ratio is 1.45, suggesting moderate liquidity but a need for careful debt management. CoreLine Soft's revenue is concentrated in a single business segment focused on AI-based medical image analysis software, with no disclosed geographic diversification. The company's operating cash flow is negative at -11,614,606,740 KRW, and its free cash flow is -17,069,904,670 KRW, indicating a reliance on external financing. Capital expenditures of -3,395,745,750 KRW suggest ongoing investment in infrastructure or technology. The company's outlook for the current fiscal year is uncertain, with no disclosed revenue growth or decline. The company's historical revenue of 4,283,668,050 KRW is relatively flat, and there is no indication of a significant growth trajectory. The company's risk assessment indicates medium liquidity risk and low dilution risk, but key flags include negative net cash after subtracting total debt. Recent events and filings do not provide specific details on the company's strategic initiatives or financial performance. The company's financial health is constrained by its negative operating and net income, and its reliance on external financing to sustain operations. The company's capital structure and liquidity position require close monitoring to assess its ability to meet short-term obligations. The company's risk profile is influenced by its high debt levels and negative cash flows, which could impact its ability to invest in growth opportunities. The company's dilution risk is low, but its liquidity risk remains a concern due to its negative net cash position. The company's financial performance and strategic direction will be critical in determining its long-term viability.
Key takeaways
  • CoreLine Soft has a high price-to-book ratio of 3.44, indicating a premium valuation relative to its book value.
  • The company's return on equity is -79.77%, and its return on assets is -35.54%, both significantly below industry norms.
  • CoreLine Soft's operating and net income are negative, with a net loss of 14,496,260,920 KRW and an operating loss of 13,444,847,760 KRW.
  • The company's liquidity risk is medium, and its dilution risk is low, but key flags include negative net cash after subtracting total debt.
  • The company's operating cash flow is negative at -11,614,606,740 KRW, and its free cash flow is -17,069,904,670 KRW, indicating a reliance on external financing.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$4.28B
Gross profit$3.93B
Operating income-$13.44B
Net income-$14.50B
R&D
SG&A
D&A
SBC
Operating cash flow-$11.61B
CapEx-$3.40B
Free cash flow-$17.07B
Total assets$40.79B
Total liabilities$22.62B
Total equity$18.17B
Cash & equivalents
Long-term debt$14.29B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$4.28B-$13.44B-$14.50B-$17.07B
FY-1$3.93B-$13.78B-$14.14B-$13.74B
FY-2$4.10B-$11.66B-$14.08B-$13.48B
FY-3$4.09B-$10.16B-$10.21B-$9.68B
FY-4$2.16B-$7.37B-$7.45B-$7.30B
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$40.79B$18.17B
FY-1$24.66B$3.66B
FY-2$15.86B$11.71B
FY-3$5.60B$2.17B$2.47B
FY-4$14.76B$11.79B$12.01B
PeriodOCFCapExFCFSBC
FY0-$11.61B-$3.40B-$17.07B
FY-1-$10.82B-$491.5M-$13.74B
FY-2-$10.28B-$173.1M-$13.48B
FY-3-$8.78B-$227.1M-$9.68B
FY-4-$7.18B-$357.6M-$7.30B
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$1.33B-$2.93B-$3.25B-$3.31B
FQ-1$974.9M-$3.59B-$3.70B-$3.46B
FQ-2$1.11B-$3.23B-$3.60B-$3.36B
FQ-3$873.9M-$3.70B-$3.95B-$6.82B
FQ-4$911.8M-$3.70B-$4.37B-$4.21B
FQ-5$845.9M-$3.45B-$3.63B-$3.70B
FQ-6$1.46B-$3.22B-$3.07B-$2.89B
FQ-7$712.7M-$3.41B-$3.06B-$2.93B
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$40.79B$18.17B
FQ-1$43.35B$21.25B
FQ-2$46.26B$24.61B
FQ-3$24.86B$3.46B
FQ-4$24.66B$3.66B
FQ-5$27.61B$7.73B
FQ-6$30.33B$11.15B
FQ-7$13.47B$10.61B
PeriodOCFCapExFCFSBC
FQ0-$11.61B-$3.40B-$3.31B
FQ-1-$9.11B-$3.19B-$3.46B
FQ-2-$6.08B-$3.13B-$3.36B
FQ-3-$3.73B-$3.08B-$6.82B
FQ-4-$10.82B-$491.5M-$4.21B
FQ-5-$8.29B-$391.5M-$3.70B
FQ-6-$5.82B-$66.2M-$2.89B
FQ-7-$3.09B-$40.3M-$2.93B
Valuation
Market price$3405.00
Market cap$62.57B
Enterprise value$76.86B
P/E
Reported non-GAAP P/E
EV/Revenue17.9
EV/Op income
EV/OCF
P/B3.4
P/Tangible book3.4
Tangible book$18.17B
Net cash-$14.29B
Current ratio1.4
Debt/Equity0.8
ROA-35.5%
ROE-79.8%
Cash conversion80.0%
CapEx/Revenue-79.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Equipment · cohort 160 companies
Metric384470Activity
Op margin-313.9%-24.0% medp25 -212.9% · p75 6.1%bottom quartile
Net margin-338.4%-20.7% medp25 -188.5% · p75 4.8%bottom quartile
Gross margin91.8%49.8% medp25 36.6% · p75 67.4%top quartile
CapEx / revenue-79.3%-4.7% medp25 -11.2% · p75 -1.8%bottom quartile
Debt / equity79.0%3.6% medp25 0.0% · p75 22.2%top quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-12 00:38 UTC#df5db8d6
Market quoteclose KRW 3405.00 · shares 0.02B diluted
no public URL
2026-05-12 00:38 UTC#b42f0696
Source: analysis-pipeline (hybrid)Generated: 2026-05-12 00:41 UTCJob: 37b4e539